Novel immunosuppressive agents with potential utility in aplastic anemia (AA).
| . | Currently Available . | In Clinical Trials for Other Indications . |
|---|---|---|
| Abbreviations: mAb, monoclonal antibody; TNF, tumor necrosis factor; IFN, interferon | ||
| Immunosuppressive agents | Anti-IL-2 mAb (Zenapax) | Anti-CD3 mAb (Nuvion) |
| Campath-1H | New mTOR inhibitors (RAD001) | |
| Rapamycin | Anti-CD11a mAb (Efalizumab) | |
| Anti-CD2 mAb (Alefacept) | ||
| Immunomodulation/tolerance | CTLA-4-Ig (Abatacept) | |
| Anti-CD154 (CD40L) mAb | ||
| Anticytokine therapy/immunomodulation | Anti-TNF-α mAb (Remicade) | Anti-IFN-γ mAb (HuZap) |
| TNF Rilg (Enbrel) | Anti-α4-integrin mAb (Natalizumab) | |
| . | Currently Available . | In Clinical Trials for Other Indications . |
|---|---|---|
| Abbreviations: mAb, monoclonal antibody; TNF, tumor necrosis factor; IFN, interferon | ||
| Immunosuppressive agents | Anti-IL-2 mAb (Zenapax) | Anti-CD3 mAb (Nuvion) |
| Campath-1H | New mTOR inhibitors (RAD001) | |
| Rapamycin | Anti-CD11a mAb (Efalizumab) | |
| Anti-CD2 mAb (Alefacept) | ||
| Immunomodulation/tolerance | CTLA-4-Ig (Abatacept) | |
| Anti-CD154 (CD40L) mAb | ||
| Anticytokine therapy/immunomodulation | Anti-TNF-α mAb (Remicade) | Anti-IFN-γ mAb (HuZap) |
| TNF Rilg (Enbrel) | Anti-α4-integrin mAb (Natalizumab) | |